Table 1 Basic characteristics of included studies
From: Prognostic value of albumin-bilirubin grade in lung cancer: a meta-analysis
Author | Year | Country | Sample size | Type of lung cancer | Treatment | Stage | Definition of ALBI grade | Endpoint | NOS |
|---|---|---|---|---|---|---|---|---|---|
Kinoshita [13] | 2021 | Japan | 947 | NSCLC | Surgery | pTNM IA-IIIA | Grade 1: score ≤ − 2.60; grade 2: score > − 2.60 and ≤ − 1.39; grade 3: score > − 1.39 | OS, PFS, CSS | 8 |
Matsukane [14] | 2021 | Japan | 140 | NSCLC | ICIs (plus chemotherapy) | cTNM IV | Grade 1: score ≤ − 2.60; grade 2a: score > − 2.60 and ≤ − 2.27; grade 2b: score > − 2.27 and ≤ − 1.39; grade 3: score > − 1.39 | OS, PFS | 7 |
Shi [15] | 2022 | China | 58 | NSCLC | ICIs (plus chemotherapy or other therapies) | cTNM III-IV | Low group: score ≤ -2.52; high group: score > -2.52 | OS | 6 |
Takada [16] | 2022 | Japan | 452 | NSCLC | ICIs (plus other therapies) | Advanced stage | Grade 1: score ≤ − 2.60; grade 2: score > − 2.60 and ≤ − 1.39; grade 3: score > − 1.39 | OS, PFS | 7 |
Qi [17] | 2023 | China | 120 | NSCLC | Surgery (plus other therapies) | pTNM I-III | Low group: score ≤ -2.18; high group: score > -2.18 | OS | 7 |
Kut [18] | 2024 | Turkey | 138 | SCLC | Chemotherapy | Extensive stage | Grade 1: score ≤ − 2.60; grade 2: score > − 2.60 and ≤ − 1.39; grade 3: score > − 1.39 | OS, PFS | 8 |
Liu [19] | 2024 | China | 135 | SCLC | Mixed | Mixed | Low group: score ≤ -2.55; high group: score > -2.55 | OS, PFS | 7 |
Xu [20] | 2024 | China | 67 | NSCLC | ICIs (plus other therapies) | Advanced stage | Grade 1: score ≤ − 2.60; grade 2a: score > − 2.60 and ≤ − 2.27; grade 2b: score > − 2.27 and ≤ − 1.39; grade 3: score > − 1.39 | OS | 6 |